Abstract:ABSTRACT The recently discovered Middle East respiratory syndrome coronavirus (MERS-CoV) continues to infect humans, with high mortality. Specific, highly effective therapeutics and vaccines against the MERS-CoV are urgently needed to save human lives and address the pandemic concerns. We identified three human monoclonal antibodies (MAbs), m336, m337, and m338, targeting the receptor (CD26/DPP4) binding domain (RBD) of the MERS-CoV spike glycoprotein from a very large naïve-antibody library (containing ∼1011 antibodies). They bound with high affinity: equilibrium dissociation constants for the three MAbs were equal to 4.2, 9.3, and 15 nM, respectively, as measured by Biacore for Fabs binding to RBD. The avidity for IgG1 m336, m337, and m338 was even higher: 99, 820, and 560 pM, respectively. The antibodies bound to overlapping epitopes that overlap the receptor binding site on the RBD as suggested by competition experiments and further supported by site-directed mutagenesis of the RBD and a docking model of the m336-RBD complex. The highest-affinity MAb, m336, neutralized both pseudotyped and live MERS-CoV with exceptional potency, 50% neutralization at 0.005 and 0.07 μg/ml, respectively, likely by competing with DPP4 for binding to the S glycoprotein. The exceptionally high neutralization activity of these antibodies and especially m336 suggests that they have great potential for prophylaxis and therapy of MERS-CoV infection in humans and as a tool for development of vaccine immunogens. The rapid identification (within several weeks) of potent MAbs suggests a possibility to use the new large antibody library and related methodology for a quick response to the public threat resulting from emerging coronaviruses. IMPORTANCE A novel human coronavirus, the Middle East respiratory syndrome coronavirus (MERS-CoV), was found to infect humans with a high mortality rate in 2012, just 1 decade after the appearance of the first highly pathogenic coronavirus, severe acute respiratory syndrome coronavirus (SARS-CoV). There are no effective therapeutics available. It is highly desirable to find an approach for rapidly developing potent therapeutics against MERS-CoV, which not only can be implemented for MERS treatment but also can help to develop a platform strategy to combat future emerging coronaviruses. We report here the identification of human monoclonal antibodies (MAbs) from a large nonimmune antibody library that target MERS-CoV. One of the antibodies, m336, neutralized the virus with exceptional potency. It therefore may have great potential as a candidate therapeutic and as a reagent to facilitate the development of vaccines against MERS-CoV.

A MERS-CoV Antibody Neutralizes a Pre-Emerging Group 2c Bat Coronavirus

A Humanized Neutralizing Antibody Against Mers-Cov Targeting the Receptor-Binding Domain of the Spike Protein

Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein to Avoid Neutralization Escape

Potent Neutralization of MERS-CoV by Human Neutralizing Monoclonal Antibodies to the Viral Spike Glycoprotein.

Exceptionally Potent Neutralization of Middle East Respiratory Syndrome Coronavirus by Human Monoclonal Antibodies

Ultrapotent Human Neutralizing Antibody Repertoires Against Middle East Respiratory Syndrome Coronavirus From A Recovered Patient

A novel neutralizing monoclonal antibody targeting the N-terminal domain of the MERS-CoV spike protein

A broadly neutralizing antibody protects against SARS-CoV, pre-emergent bat CoVs, and SARS-CoV-2 variants in mice

Evaluation of candidate vaccine approaches for MERS-CoV

Functional reconstitution of the MERS CoV receptor binding motif

Structure defining of ultrapotent neutralizing nanobodies against MERS-CoV with novel epitopes on receptor binding domain

Molecular Characteristics, Functions, and Related Pathogenicity of MERS-CoV Proteins

Identification of Human Neutralizing Antibodies Against Mers-Cov and Their Role in Virus Adaptive Evolution

Structural basis for the neutralization of MERS-CoV by a human monoclonal antibody MERS-27

Neutralizing Monoclonal Antibodies as Promising Therapeutics against Middle East Respiratory Syndrome Coronavirus Infection.

Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses

Protein nanoparticle vaccines induce potent neutralizing antibody responses against MERS-CoV

A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (Mers-Cov) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy Against MERS-CoV

A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein.

A Safe and Convenient Pseudovirus-Based Inhibition Assay to Detect Neutralizing Antibodies and Screen for Viral Entry Inhibitors Against the Novel Human Coronavirus MERS-CoV

Towards a Solution to MERS: Protective Human Monoclonal Antibodies Targeting Different Domains and Functions of the MERS-coronavirus Spike Glycoprotein